A multi-vector, multi-envelope HIV-1 vaccine

Hurwitz, Julia L., Zhan, Xiaoyan, Brown, Scott A., Bonsignori, Mattia, Stambas, John, Lockey, Timothy D., Jones, Bart, Surman, Sherri, Sealy, Robert, Freiden, Pam, Branum, Kristen and Slobod, Karen S. 2007, A multi-vector, multi-envelope HIV-1 vaccine, The Journal of pediatric pharmacology and therapeutics, vol. 12, no. 2, pp. 68-76.

Attached Files
Name Description MIMEType Size Downloads

Title A multi-vector, multi-envelope HIV-1 vaccine
Author(s) Hurwitz, Julia L.
Zhan, Xiaoyan
Brown, Scott A.
Bonsignori, Mattia
Stambas, JohnORCID iD for Stambas, John orcid.org/0000-0002-5690-2551
Lockey, Timothy D.
Jones, Bart
Surman, Sherri
Sealy, Robert
Freiden, Pam
Branum, Kristen
Slobod, Karen S.
Journal name The Journal of pediatric pharmacology and therapeutics
Volume number 12
Issue number 2
Start page 68
End page 76
Total pages 22 p.
Publisher Pediatric Pharmacology Adovacy Group
Place of publication Littleton, Colorado
Publication date 2007
ISSN 1551-6776
Keyword(s) HIV (Viruses) -- Treatment
Summary The St. Jude Children's Research Hospital (St. Jude) HIV-1 vaccine program is based on the observation that multiple, antigenically distinct HIV-1 envelope protein structures are capable of mediating HIV-1 infection. A cocktail vaccine comprising representatives of these diverse structures (immunotypes) is therefore considered necessary to elicit lymphocyte populations that prevent HIV-1 infection. This strategy is reminiscent of that used to design a currently licensed and successful 23-valent pneumococcus vaccine. Three recombinant vector systems are used for the delivery of envelope cocktails (DNA, vaccinia virus, and purified protein) and each of these has been tested individually in phase I safety trials. A fourth clinical trial, in which diverse envelopes and vectors are combined in a prime-boost vaccination regimen, has been FDA-approved and is expected to commence in 2007. This trial will continue to test the hypothesis that a multivector, multi-envelope vaccine can elicit diverse 8- and T-cell populations that can prevent HIV-1 infections in humans.
Language eng
Field of Research 110704 Cellular Immunology
Socio Economic Objective 920109 Infectious Diseases
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2007, Pediatric Pharmacology Adovacy Group
Persistent URL http://hdl.handle.net/10536/DRO/DU:30031199

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 654 Abstract Views, 11 File Downloads  -  Detailed Statistics
Created: Wed, 17 Nov 2010, 09:16:53 EST by Jane Moschetti

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.